Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in

10/8/2017 17:00

Llamada en conferencia Chiasma Inc

Chiasma Inc Conference call will be held on 10-ago-2017. During the earnings conference call's session Chiasma Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Chiasma Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing our proprietary Transient Permeability Enhancer, or TPE, technology platform, we seek to develop oral medications that are currently available only as injections. We are currently conducting an international Phase 3 clinical trial - MPOWERED - of oral octreotide capsules, conditionally trade-named "MYCAPSSA" and referred to herein as octreotide capsules, for the maintenance treatment of adult patients with acromegaly to support a potential submission of a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA. Octreotide capsules, which we developed utilizing our TPE platform, is an oral formulation of octreotide, an analog of somatostatin, a natural inhibitor of growth hormone secretion.    
Leer más Llamada en conferencia

Chiasma Inc (CHMA)

275 Wyman Street, Waltham Massachusetts 02451, United States